



European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

Declaration on compliance with the ENCePP Code of Conduct for ENCePP Seal studies¹

The (primary) lead investigator and a person authorised to sign on behalf of the coordinating study entity hereby declare for the purpose of conducting the study <include here study name and identifier/reg.no.>

Utilisation of antiepileptic medicines in girls and women of childbearing potential

- to follow the rules and principles for the independent and transparent conduct of pharmacoepidemiological and pharmacovigilance studies of the current version of the ENCePP Code of Conduct²;
- to inform the ENCePP Secretariat, without delay, of any change or decision to change that constitutes a deviation from the provisions of this Code.

It is of note that the (primary) lead investigator and the person authorised to sign on behalf of the coordinating study entity may be identical.

Name of (primary) lead investigator: DR RACHEL CHARLTON					
Date: 16/05/2016 (dd/mm/yyyy) Stamp (if applicable) and signature: **R Charlton**					
Name of the coordinating study entity: UNIVERSITY OF BATH					
Address:					
DEPARTMENT OF PHARMACY AND PHARMACOLOGY UNIVERSITY OF BATH CLAVERTON DOWN BATH BA2 7AY					
Name of person authorised to sign on behalf of the coordinating study entity [if different from					
(primary) lead investigator]:					
Date: (dd/mm/yyyy)					
Stamp (if applicable) and signature:					

The (primary) lead investigator should also complete, sign and date the Checklist of the ENCePP Code of Conduct for ENCePP Seal studies.

² Adopted Code and any revision thereof at the time of signature of the declaration.

Reset Form

¹ Complete the declaration on screen, then print, stamp (if applicable) and sign.